Cardarine comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
cffDNA originates from placental trophoblasts. Fetal DNA is fragmented when placental microparticles are shed into the maternal blood circulation. cffDNA fragments are approximately 200 base pairs (bp) in length. They are significantly smaller than maternal DNA fragments. The difference in size allows cffDNA to be distinguished from maternal DNA fragments. Approximately 11 to 13.4 percent of the cell-free DNA in maternal blood is of fetal origin. The amount varies widely from one pregnant woman to another. cffDNA is present after five to seven weeks gestation. The amount of cffDNA increases as the pregnancy progresses. The quantity of cffDNA in maternal blood diminishes rapidly after childbirth. Two hours after delivery, cffDNA is no longer detectable in maternal blood. Analysis of cffDNA may provide earlier diagnosis of fetal conditions than current techniques. As cffDNA is found in maternal blood, sampling carries no associated risk of spontaneous abortion. cffDNA analysis has the same ethical and practical issues as other techniques such as amniocentesis and chorionic villus sampling. Some disadvantages of sampling cffDNA include a low concentration of cffDNA in maternal blood; variation in the quantity of cffDNA between individuals; a high concentration of maternal cell free DNA compared to the cffDNA in maternal blood.
==== Poland ==== There is a large pool of think tanks in Poland on a wide variety of subjects. The oldest state-sponsored think tank is The Western Institute in Poznań (Polish: Instytut Zachodni). The second oldest is the Polish Institute of International Affairs (PISM) established in 1947. Another notable state-sponsored think tank is the Centre for Eastern Studies (OSW), which specializes in the countries neighboring Poland and in the Baltic Sea region, the Balkans, Turkey, the Caucasus and Central Asia. Among the private think tanks notable organizations include the Institute for Structural Research (IBS) on economic policy, The Casimir Pulaski Foundation on foreign policy, the Institute of Public Affairs (ISP) on social policy, and the Sobieski Institute.
In early January 2011, the Colombian army said that FARC had some 18,000 members, with 9,000 of those forming part of the militias. The army claimed to have "identified" at least 1,400 such militia members in the FARC strongholds of Valle del Cauca and Cauca in 2011. In June 2011, Colombian chief of staff Edgar Cely claimed that FARC wanted to "urbanize their actions", which could partly explain the increased guerrilla activity in Medellín, and particularly Cali. Jeremy McDermott, co-director of InSight Crime, estimated in 2011 that FARC may have some 30,000 "part-time fighters", with supporters making up the rebel militia network instead of armed uniformed combatants. Also in 2011, the Colombian Congress issued a statement claiming that FARC had a "strong presence" in roughly one third of Colombia, while their attacks against security forces "continued to rise" throughout 2010 and 2011. In 2012, the Colombia Military launched the Espada de Honor War Plan, an aggressive counterinsurgency strategy aiming to dismantle FARC's structure, both militarily and financially. The plan targeted FARC leadership and focused on eliminating 15 of the most powerful economic and military fronts.
Sources: en.wikipedia.org
=== Competing narratives === In the years immediately following the revolution, narratives applied both by Romanians and the international audience competed for an interpretation of the events of 1989. Within Romania, myths interpreting it as "false" or "stolen" by the FSN correlated to one's level of disagreement with the political organization, while those painting the events as a pure, "spontaneous revolution" largely aligned with support for the FSN. In addition, the FSN itself attempted to construct its own narrative of the revolution, with its leaders placed abruptly at the center by popular will. This interpretation was largely challenged by FSN opponents.
Glucose is a ubiquitous fuel in biology. It is used as an energy source in organisms, from bacteria to humans, through either aerobic respiration, anaerobic respiration, or fermentation. Glucose is the human body's key source of energy, through aerobic respiration, providing about 3.75 kilocalories (16 kilojoules) of food energy per gram. Breakdown of carbohydrates (e.g., starch) yields mono- and disaccharides, most of which is glucose. Through glycolysis and later in the reactions of the citric acid cycle and oxidative phosphorylation, glucose is oxidized to eventually form carbon dioxide and water, yielding energy mostly in the form of adenosine triphosphate (ATP). The insulin reaction, and other mechanisms, regulate the concentration of glucose in the blood. The physiological caloric value of glucose, depending on the source, is 16.2 kilojoules per gram or 15.7 kJ/g (3.74 kcal/g). The high availability of carbohydrates from plant biomass has led to a variety of methods during evolution, especially in microorganisms, to use glucose for energy and carbon storage. Differences exist in which end product can no longer be used for energy production. The presence of individual genes, and their gene products, the enzymes, determine which reactions are possible. The metabolic pathway of glycolysis is used by almost all living beings. An essential difference in the use of glycolysis is the recovery of NADPH as a reductant for anabolism that would otherwise have to be generated indirectly.
With Fábregas breaking into the first team, Wenger chose to deviate from their counter-attacking style, to a more possession based one. In 2009–10, he instituted a fluid 4–3–3 formation to benefit from Fàbregas' creativity, and since the player's departure, had remodelled the system to 4–1–4–1 and 4–2–3–1. During the latter half of the 2016–17 Premier League season, Wenger switched to a 3–4–3 formation, similar to Antonio Conte's Chelsea first used against Middlesbrough in a 2–1 win. Wenger proved able to implement his entertaining vision of football, particularly at Arsenal. His team's 5–1 win against Portsmouth in March 2004 was likened to "the magnificently fluid Ajax of the early 70s", and greeted with a standing ovation by the opposition supporters, as the Arsenal players left the field. Wenger's style of play, however, has been criticised for inefficiency and a lack of variation to go with technique. He is not renowned for making game-changing substitutions, nor had his tactics helped his teams overcome flexible opponents. His ideals are noticeably different from the pragmatic approach of his rivals, though he has assembled teams to produce disciplined performances, markedly the 2005 FA Cup Final against Manchester United. Defeats in the big games during 2013–14 led to Wenger compromising his attack-minded principles in favour of keeping it tight.
=== Agriculture === Similar to other areas, Ningxia has seen a gradual decline of its peasant population due to rural–urban migration. Despite this, the great majority (62.8 percent) was still agricultural at the time of the survey. Animal husbandry is important for the regional economy. In the main pastoral county, Yanchi, it is even the leading industry when specified for the primary sector. The dominant grazing animals are sheep and goat. In the (semi-)pastoral regions, herders engage in a mixed sedentary farming operation of dryland agriculture and extensive animal husbandry, while full nomadic pastoralism is no longer practiced. Since a cattle breeding plan was implemented in 2002, the province has become one of China's main dairy production areas. Ningxia is the principal region of China where wolfberries are grown. Other specialties of Ningxia are licorice, products made from Helan stone, fiddlehead and products made from sheepskin. Ningxia wines are a promising area of development. The Chinese authorities have given approval to the development of the eastern base of the Helan Mountains as an area suitable for wine production. Several large Chinese wine companies including Changyu and Dynasty Wine have begun development in the western region of the province. Together they now own 20,000 acres of land for wine plantations and Dynasty has ploughed 100 million yuan into Ningxia. In addition, the major oil company China Petroleum and Chemical Corporation has founded a grape plantation near the Helan Mountains.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.